top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 4 hours ago
  • 1 min read

10/03/2026




















Redx’s RXC008 granted US FDA fast track designation for fibrostenotic CD (Ref)


Redx Pharma announced that the US FDA had granted fast track designation to RXC008 (a GI-restricted pan-ROCK inhibitor) for the treatment of patients with fibrostenotic crohn’s disease (CD)


  • Lisa Anson, CEO, Redx Pharma: “Redx have been working closely with the FDA and the STAR consortium to define the regulatory pathway for this disease and following our positive pre-clinical and Phase 1 data, we look forward to commencing our Phase 2 study later this year.”





bottom of page